Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa.

Cindy Zadikoff Werner PoeweJames T BoydLars BergmannHoria IjacuPavnit KukrejaWeining Z RobiesonJanet BeneshAngelo Antonini

Published in: Parkinson's disease (2020)

Patients who require ≥2000 mg/day LCIG exhibited a safety profile comparable to the established safety/tolerability of LCIG with similar clinical improvements. Higher AEs were noted but within what is accepted for LCIG. Continuous administration of LCIG is beneficial to advanced PD patients who require very high doses of levodopa.

Keyphrases

parkinson disease
deep brain stimulation
open label
randomized controlled trial
clinical trial
combination therapy
replacement therapy
study protocol